https://doi.org/10.55788/f90cdf34
“There are regional differences in cardiac arrest survival due to variations in infrastructure, resources, and personnel,” Dr Tiffany Patterson (King’s College London, UK) pointed out [1]. “The standard-of-care for patients with resuscitated OHCA is to transfer them to the nearest emergency department. However, post-arrest care may best be delivered at a specialised centre.” The ARREST trial (NCT03880565) assessed whether transferring patients with resuscitated non-ST elevated OHCA to a specialised centre improves their chance of survival compared with delivery to the nearest emergency department [1,2]. The study included 32 emergency departments and 7 specialised cardiac arrest centres in London. Ambulance paramedics randomised pre-hospital patients (n=862) 1:1 to either a transfer to the nearest emergency department or a transfer to a specialised care centre. The primary outcome was 30-day all-cause mortality.
At 30 days, no differences were observed between the standard-of-care/emergency department group and the cardiac arrest centre group in terms of 30-day all-cause mortality (risk ratio 1.00; 95% CI 0.90–1.11; P=0.96). Secondary outcomes, such as 3-month mortality and neurological outcomes at discharge, confirmed that transfer to a specialised cardiac arrest centre did not result in significant health benefits for patients.
- Patterson T, et al. ARREST Trial: expedited transfer to a cardiac arrest centre for non-ST elevation OHCA. Hot Line Session 5, ESC Congress 2023, 25–28 August, Amsterdam, the Netherlands.
- Patterson T, et al. Lancet. 2023; Aug 27. DOI:10.1016/S0140-6736(23)01351-X.
Copyright ©2023 Medicom Medical Publishers
Posted on
Previous Article
« Angiography vs OCT vs IVUS guidance for PCI: a network meta-analysis Next Article
The optimal duration of anticoagulation therapy in cancer patients with DVT »
« Angiography vs OCT vs IVUS guidance for PCI: a network meta-analysis Next Article
The optimal duration of anticoagulation therapy in cancer patients with DVT »
Table of Contents: ESC 2023
Featured articles
How to manage arterial thrombosis and thromboembolism in COVID-19?
2023 ESC Guidelines & Updates
Heart failure: the 2023 update
Guidelines for Acute Coronary Syndrome
Guidelines for the management of cardiomyopathies
Cardiovascular disease and diabetes: new guidelines
Guidelines for the management of endocarditis
Trial Updates in Heart Failure
Traditional Chinese medicine successful in HFrEF
CRT upgrade benefits patients with HFrEF and an ICD
Catheter ablation saves lives in end-stage HF with AF
Meta-analysis: Does FCM improve clinical outcomes in HF?
HEART-FID: Is intravenous ferric carboxymaltose helpful in HFrEF with iron deficiency?
Natriuresis-guided diuretic therapy to facilitate decongestion in acute HF
DICTATE-AHF: Early dapagliflozin to manage acute HF
STEP-HFpEF: Semaglutide safe and efficacious in HFpEF plus obesity
Key Research on Prevention
Does colchicine prevent perioperative AF and MINS?
Diagnostic tool doubles cardiovascular diagnoses in patients with COPD or diabetes
Inorganic nitrate strongly reduces CIN in high-risk patients undergoing angiography
Finetuning Antiplatelet and Anticoagulation Therapy
Should we use anticoagulation in AHRE to prevent stroke?
Results of FRAIL-AF trial suggest increased bleeding risk with DOACs
The optimal duration of anticoagulation therapy in cancer patients with DVT
DAPT or clopidogrel monotherapy after stenting in high-risk East-Asian patients?
Assets for ACS and PCI Optimisation
Immediate or staged revascularisation in STEMI plus multivessel disease?
Lp(a) and cardiovascular events: which test is the best?
No benefit of extracorporeal life support in MI plus cardiogenic shock
Functional revascularisation outperforms culprit-only strategy in older MI patients
Can aspirin be omitted after PCI in patients with high bleeding risk?
Angiography vs OCT vs IVUS guidance for PCI: a network meta-analysis
OCTOBER trial: OCT-guided PCI improves clinical outcomes in bifurcation lesions
Other
Minimising atrial pacing does not reduce the risk for AF in sinus node disease
ARAMIS: Can anakinra alleviate acute myocarditis?
Expedited transfer to a specialised centre does not improve cardiac arrest outcomes
Acoramidis improves survival and functional status in ATTR-CM
Related Articles
October 30, 2023
Guidelines for Acute Coronary Syndrome
October 30, 2023
STEP-HFpEF: Semaglutide safe and efficacious in HFpEF plus obesity
© 2024 Medicom Medical Publishers. All rights reserved. Terms and Conditions | Privacy Policy
HEAD OFFICE
Laarderhoogtweg 25
1101 EB Amsterdam
The Netherlands
T: +31 85 4012 560
E: publishers@medicom-publishers.com
